The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce ...

The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with ...

Concizumab is a tissue factor pathway inhibitor antagonist that enhances factor Xa production during the initiation phase of coagulation. This production improves thrombin generation and clot ...

Researchers from Nanjing University and Peking University presented the discovery and preclinical characterization of novel NLRP3 inhibitors as potential therapeutic candidates for the treatment of ...